A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 672-680

Springer Publishing Company

Access to resources Recommend Favorite

Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer

By Méndez M.   Alfonso P.   Pujol E.   González E.   Castañon C.   Cerezuela P.   López-Mateos Y.   Cruz J.  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 243-251

Springer Publishing Company

Access to resources Recommend Favorite

Irinotecan plus fluorouracil and folinic acid should be the comparator regimen in clinical trials involving patients with metastatic colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1232, 2000-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status

By Kang Myoung  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1607-1613

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacogenomics of Fluorouracil, Irinotecan, and Oxaliplatin in Hepatic Metastases of Colorectal Cancer: Clinical Implications

By Lentz Frederike   Tran Agnès   Rey Elisabeth   Pons Gérard   Tréluyer Jean-Marc  

American Journal of PharmacoGenomics, Vol. 5, Iss. 1, 2005-01 ,pp. : 21-33

Adis International

Access to resources Recommend Favorite